The anti-breast cancer drugs such as Vemurafenib, Ponatinib, Crizotinib, Dacomitinib, Regorafenib, Pazopanib, Neratinib, Midostaurin, Nintedanib, Bosutinib, Sunitinib, Vandetanib, Dasatinib, Sorafenib, Lapatinib, Everolimus, Erlotinib, Temsirolimus, Gefitinib, Imatinib, and Rapamycin showed interactions with the genes EGFR and ERBB2. This evidence concerns the gene ERBB2 and breast carcinoma.